Abstract
Acute kidney injury (AKI) and chronic kidney disease (CKD) are conditions that substantially increase morbidity and mortality. New biomarker plasma neutrophil gelatinase –associated lipocalin (NGAL) can identify the patients with AKI and CKD earlier which helps to intervene and modify outcome.The aim of the study was to determine whether plasma NGAL levels could be used to distinguish AKI and CKD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
